Edition:
United Kingdom

Medicines Co (MDCO.OQ)

MDCO.OQ on NASDAQ Stock Exchange Global Select Market

20.00USD
18 Jan 2019
Change (% chg)

$0.05 (+0.25%)
Prev Close
$19.95
Open
$19.94
Day's High
$20.01
Day's Low
$19.15
Volume
268,330
Avg. Vol
385,637
52-wk High
$41.57
52-wk Low
$16.71

Latest Key Developments (Source: Significant Developments)

The Medicines Company Announces 5Th Review Of Un-Blinded Data
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Medicines Co ::THE MEDICINES COMPANY ANNOUNCES 5TH REVIEW OF UN-BLINDED DATA AND RECOMMENDATION BY INDEPENDENT DATA MONITORING COMMITTEE TO CONTINUE INCLISIRAN PHASE 3 TRIALS.MEDICINES CO - IDMC HAS RECOMMENDED THAT TRIALS CONTINUE AS DESIGNED AND CONDUCTED, WITHOUT MODIFICATION.  Full Article

The Medicines Company Prices $150 Mln Of Convertible Notes
Friday, 14 Dec 2018 

Dec 13 (Reuters) - Medicines Co ::THE MEDICINES COMPANY PRICES $150 MILLION OF CONVERTIBLE NOTES.PRICED ITS PRIVATE OFFERING OF $150 MILLION IN AGGREGATE PRINCIPAL AMOUNT OF ITS CONVERTIBLE SENIOR NOTES DUE 2024.SAYS NOTES WILL BEAR INTEREST AT A RATE OF 3.50% PER YEAR, PAYABLE SEMI-ANNUALLY.  Full Article

The Medicines Company Announces Intention To Offer $150 Mln Of Convertible Notes
Wednesday, 12 Dec 2018 

Dec 12 (Reuters) - Medicines Co ::THE MEDICINES COMPANY ANNOUNCES INTENTION TO OFFER $150 MILLION OF CONVERTIBLE NOTES.MEDICINES CO - EXPECTS TO USE NET PROCEEDS OF OFFERING TO FUND ITS DEVELOPMENT OF INCLISIRAN.  Full Article

Medicines Company Appoints Mark Timney As CEO
Tuesday, 11 Dec 2018 

Dec 11 (Reuters) - Medicines Co ::THE MEDICINES COMPANY APPOINTS MARK TIMNEY AS CHIEF EXECUTIVE OFFICER.MEDICINES CO - TIMNEY WILL SUCCEED CLIVE MEANWELL AS CEO.MEDICINES CO - CLIVE MEANWELL HAS BEEN APPOINTED BY BOARD TO SERVE AS CHIEF INNOVATION OFFICER.MEDICINES CO - TIMNEY'S APPOINTMENT EFFECTIVE IMMEDIATELY.  Full Article

The Medicines Company Reports Third-Quarter Loss Per Share $0.70 From Continuing Operations
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Medicines Co ::THE MEDICINES COMPANY REPORTS THIRD-QUARTER 2018 RESULTS.Q3 GAAP LOSS PER SHARE $0.70 FROM CONTINUING OPERATIONS.Q3 ADJUSTED NON-GAAP LOSS PER SHARE $0.70 FROM CONTINUING OPERATIONS.Q3 EARNINGS PER SHARE VIEW $-0.55 -- THOMSON REUTERS I/B/E/S.  Full Article

The Medicines Company Announces Recommendation By Independent Data Monitoring Committee To Continue Inclisiran
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Medicines Co ::THE MEDICINES COMPANY ANNOUNCES RECOMMENDATION BY INDEPENDENT DATA MONITORING COMMITTEE TO CONTINUE INCLISIRAN PHASE III TRIALS FOLLOWING FOURTH REVIEW OF UNBLINDED DATA.MEDICINES CO - PHASE III TRIALS OF INCLISIRAN PROGRESSING AS PLANNED WITH NO MATERIAL SAFETY OBSERVATIONS TO DATE.MEDICINES CO - IDMC FOR ONGOING INCLISIRAN PHASE III TRIALS HAS RECOMMENDED THAT TRIALS CONTINUE AS DESIGNED AND CONDUCTED, WITHOUT MODIFICATION.MEDICINES CO - DATA READOUT FOR INCLISIRAN PHASE III PROGRAM EXPECTED IN SECOND HALF OF 2019.  Full Article

The Medicines Company Reports Q2 GAAP Loss Per Share $0.74
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Medicines Co ::THE MEDICINES COMPANY REPORTS SECOND-QUARTER 2018 RESULTS.Q2 GAAP LOSS PER SHARE $0.74 FROM CONTINUING OPERATIONS.Q2 ADJUSTED NON-GAAP LOSS PER SHARE $0.63 FROM CONTINUING OPERATIONS.Q2 EARNINGS PER SHARE VIEW $-0.60 -- THOMSON REUTERS I/B/E/S.AT JUNE 30, CO HAD $162.5 MILLION IN CASH AND CASH EQUIVALENTS, COMPARED TO $151.4 MILLION AT END OF 2017.  Full Article

Medicines Co Announces Recommendation By Independent Committee To Continue Inclisiran Phase III Trials
Wednesday, 27 Jun 2018 

June 27 (Reuters) - Medicines Co ::THE MEDICINES COMPANY ANNOUNCES RECOMMENDATION BY INDEPENDENT DATA MONITORING COMMITTEE TO CONTINUE INCLISIRAN PHASE III TRIALS FOLLOWING THIRD REVIEW OF UNBLINDED DATA.MEDICINES CO - PHASE III TRIALS OF INCLISIRAN PROGRESSING AS PLANNED WITH NO MATERIAL SAFETY OBSERVATIONS TO DATE.MEDICINES CO - "CONTINUE TO ADVANCE INCLISIRAN PHASE III PROGRAM ON HIGHLY-EFFICIENT BASIS, WITH DATA READOUT EXPECTED IN SECOND HALF OF 2019".  Full Article

The Medicines Company Announces Chief Financial Officer Transition
Wednesday, 28 Mar 2018 

March 28 (Reuters) - Medicines Co ::THE MEDICINES COMPANY ANNOUNCES CHIEF FINANCIAL OFFICER TRANSITION.APPOINTS CHRISTOPHER VISIOLI AS CHIEF FINANCIAL OFFICER AND TREASURER OF COMPANY​.‍ VISIOLI SUCCEEDS WILLIAM O'CONNOR, WHO IS RETIRING FROM COMPANY AFTER SERVING AS CHIEF ACCOUNTING OFFICER AND THEN CFO.  Full Article

State Street Global Advisors Announces Impact Of Receiving Settlement Payment
Friday, 5 Jan 2018 

Jan 5 (Reuters) - State Street Corp ::STATE STREET GLOBAL ADVISORS ANNOUNCES IMPACT OF RECEIVING SETTLEMENT PAYMENT.SPDR EXCHANGE TRADED FUND - RECEIVED PAYMENT AS AUTHORIZED CLAIMANT FROM A CLASS ACTION SETTLEMENT RELATED TO MEDICINES COMPANY​.  Full Article